

CS/NSE/BSE/UFR/2013-14  
November 11, 2013

**TO  
THE MANAGER  
LISTING DEPARTMENT,  
NATIONAL STOCK EXCHANGE OF INDIA LTD  
EXCHANGE PLAZA, BANDRA- KURLA  
COMPLEX, BANDRA (E), MUMBAI-400 051**

**Stock Code - SUVEN EQ**

**TO  
THE GENERAL MANAGER  
DEPARTMENT OF CORPORATE SERVICES  
BOMBAY STOCK EXCHANGE LTD  
25<sup>TH</sup> FLOOR, P. J. TOWERS,  
DALAL STREET, MUMBAI - 400 001**

**Stock Code - 530239**

Dear Sir/Madam,


**Sub: Notification of Un-audited Financial Results for the quarter ended September 30, 2013 – Clause 41**

.....

With reference to the above subject, we are forwarding here with **Un-audited Financial Results of our Company for three/six months ended 30th September, 2013** in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the second quarter in its meeting held on 11<sup>th</sup> November, 2013 and **Limited Review Report of Auditors of the Company.**

**Please find enclosed Press release of our company.** We request you to take these documents on your records.

Thanking you,  
Yours faithfully,  
For **SUVEN LIFE SCIENCES LIMITED**

  
**K HANUMANTHA RAO**  
Company Secretary

**SUVEN LIFE SCIENCES LIMITED**

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India  
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com), [www.suven.com](http://www.suven.com)

## News Release

### Suven Q2 PAT up by 602% to Rs.45.55 Cr

**HYDERABAD, INDIA (11 Nov' 2013)** – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services ( CRAMS) company today announced its un-audited financial results for the quarter ended 30<sup>th</sup> Sept 2013. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 11<sup>th</sup> Nov 2013 at Hyderabad.

Financial Highlights for the 2<sup>nd</sup> Quarter ended Sept' 2013:

|                          |                                             |
|--------------------------|---------------------------------------------|
| <b>Growth in revenue</b> | <b>Rs 1515 Mn vs.Rs 503 Mn - Up by 202%</b> |
| <b>Growth in PAT</b>     | <b>Rs 455 Mn vs. Rs 65 Mn - Up by 602%</b>  |
| <b>Growth in EBIDTA</b>  | <b>Rs 715 Mn vs. Rs 110 Mn - Up by 550%</b> |

Financial Highlights for the Half year ended Sept' 2013:

|                          |                                              |
|--------------------------|----------------------------------------------|
| <b>Growth in revenue</b> | <b>Rs 2634 Mn vs.Rs 1209 Mn - Up by 118%</b> |
| <b>Growth in PAT</b>     | <b>Rs 753 Mn vs. Rs 144 Mn - Up by 421%</b>  |
| <b>Growth in EBIDTA</b>  | <b>Rs 1177 Mn vs. Rs 249 Mn - Up by 374%</b> |

The growth in profit was a result of one new product, in addition to 2 products already commercialized during first quarter, totaling 3 products under CRAMS.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 258 Mn (9.80% on revenue) for the Half year ended Sept' 2013.

SUVN-502 entered phase 1b clinical trial in USA.

**For more information on Suven please visit our Web site at <http://www.suven.com>**

**Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*

#### **SUVEN LIFE SCIENCES LIMITED**

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India  
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com), [www.suven.com](http://www.suven.com)